PHILADELPHIA--(BUSINESS WIRE)--Integral Molecular, a leader in membrane protein antibody discovery, announces the issuance of a new patent and patent family protecting the composition of matter for its Lipoparticle technology. Lipoparticles represent a proprietary Integral Molecular technology that feature highly-concentrated membrane proteins in their native conformation for drug and antibody discovery against high-value targets including G protein-coupled receptors (GPCRs), ion channels, and transporters. This represents the third issued patent family surrounding the Lipoparticle technology.
US Patent No. 8,574,590 was granted by the USPTO on November 5, 2013 to Integral Molecular, expanding the company’s landscape of Lipoparticle intellectual property. Integral Molecular is the exclusive world-wide patent holder or licensee of all Lipoparticle patents, and licensed Lipoparticle technology is available only from Integral Molecular. Additional patents covering Lipoparticle technology are pending.
“Complex membrane proteins are exceptionally difficult to study, and there are currently no FDA approved antibody therapeutics against high-value targets such as GPCRs, ion channels and transporters,” said Dr. Benjamin Doranz, President of Integral Molecular. “Lipoparticles have become an established route for membrane protein antibody discovery, and our growing patent landscape strengthens our commitment to the discovery of these therapeutically important antibodies.”
Integral Molecular offers custom Lipoparticles produced with user-specified target membrane proteins on a fee-for-service basis, as well as ReadyReceptor® Lipoparticles that contain pre-validated, high-concentration membrane protein targets. Each lot of Lipoparticles is quality controlled and provided with technical protocols for relevant applications, including antibody generation and screening, biosensor assays, and ELISA binding assays. Lipoparticles can be biotinylated or fluorescently labeled to accommodate specialized applications.
About Integral Molecular
Integral Molecular is a research-driven biotechnology company creating a pipeline of therapeutic antibodies against under-exploited membrane protein targets, including GPCRs, ion channels, and transporters, using its proprietary MPS Discovery EngineTM. This platform is built on the company’s Lipoparticle and Shotgun Mutagenesis technologies as well as its 10+ years of experience optimizing membrane proteins, enabling the isolation, characterization, and engineering of monoclonal antibodies against otherwise intractable membrane protein targets. The company currently has therapeutic programs focused on pain, cancer, and infectious diseases.
